|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRIM16L |
Gene summary for TRIM16L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRIM16L | Gene ID | 147166 |
| Gene name | tripartite motif containing 16 like | |
| Gene Alias | TRIM70 | |
| Cytomap | 17p11.2 | |
| Gene Type | pseudo | GO ID | GO:0005575 | UniProtAcc | Q309B1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 147166 | TRIM16L | P76T-E | Human | Esophagus | ESCC | 1.07e-04 | 1.07e-01 | 0.1207 |
| 147166 | TRIM16L | P80T-E | Human | Esophagus | ESCC | 2.27e-05 | 1.37e-01 | 0.155 |
| 147166 | TRIM16L | P83T-E | Human | Esophagus | ESCC | 1.54e-56 | 1.42e+00 | 0.1738 |
| 147166 | TRIM16L | P89T-E | Human | Esophagus | ESCC | 3.45e-02 | 2.57e-01 | 0.1752 |
| 147166 | TRIM16L | P107T-E | Human | Esophagus | ESCC | 3.89e-58 | 1.36e+00 | 0.171 |
| 147166 | TRIM16L | P127T-E | Human | Esophagus | ESCC | 5.10e-03 | 1.40e-01 | 0.0826 |
| 147166 | TRIM16L | P128T-E | Human | Esophagus | ESCC | 2.75e-05 | 1.77e-01 | 0.1241 |
| 147166 | TRIM16L | P130T-E | Human | Esophagus | ESCC | 6.11e-21 | 5.34e-01 | 0.1676 |
| 147166 | TRIM16L | HCC1_Meng | Human | Liver | HCC | 3.65e-81 | 6.38e-01 | 0.0246 |
| 147166 | TRIM16L | HCC2_Meng | Human | Liver | HCC | 2.69e-03 | 2.51e-02 | 0.0107 |
| 147166 | TRIM16L | HCC1 | Human | Liver | HCC | 6.72e-03 | 2.38e+00 | 0.5336 |
| 147166 | TRIM16L | HCC2 | Human | Liver | HCC | 9.54e-40 | 4.40e+00 | 0.5341 |
| 147166 | TRIM16L | Pt14.a | Human | Liver | HCC | 1.49e-05 | 2.90e-01 | 0.0169 |
| 147166 | TRIM16L | S014 | Human | Liver | HCC | 7.93e-06 | 2.11e-01 | 0.2254 |
| 147166 | TRIM16L | S015 | Human | Liver | HCC | 2.27e-03 | 1.20e-01 | 0.2375 |
| 147166 | TRIM16L | S016 | Human | Liver | HCC | 7.61e-06 | 2.31e-01 | 0.2243 |
| 147166 | TRIM16L | S027 | Human | Liver | HCC | 6.81e-11 | 8.70e-01 | 0.2446 |
| 147166 | TRIM16L | S028 | Human | Liver | HCC | 2.44e-25 | 1.04e+00 | 0.2503 |
| 147166 | TRIM16L | S029 | Human | Liver | HCC | 9.69e-19 | 9.66e-01 | 0.2581 |
| 147166 | TRIM16L | C04 | Human | Oral cavity | OSCC | 5.65e-05 | 2.25e-01 | 0.2633 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRIM16L | SNV | Missense_Mutation | c.415N>C | p.Tyr139His | p.Y139H | Q309B1 | protein_coding | tolerated(0.74) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TRIM16L | SNV | Missense_Mutation | rs752949316 | c.530G>A | p.Arg177His | p.R177H | Q309B1 | protein_coding | tolerated(0.13) | benign(0.299) | TCGA-EX-A69M-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| TRIM16L | SNV | Missense_Mutation | c.828C>G | p.Phe276Leu | p.F276L | Q309B1 | protein_coding | tolerated(0.08) | benign(0.334) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| TRIM16L | SNV | Missense_Mutation | c.44C>T | p.Ala15Val | p.A15V | Q309B1 | protein_coding | tolerated(0.12) | benign(0.022) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| TRIM16L | SNV | Missense_Mutation | rs368943120 | c.409N>T | p.Arg137Cys | p.R137C | Q309B1 | protein_coding | tolerated(0.11) | benign(0.431) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| TRIM16L | SNV | Missense_Mutation | rs749951466 | c.977N>T | p.Ala326Val | p.A326V | Q309B1 | protein_coding | tolerated(1) | benign(0.001) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TRIM16L | SNV | Missense_Mutation | rs552209237 | c.976N>A | p.Ala326Thr | p.A326T | Q309B1 | protein_coding | tolerated(0.52) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TRIM16L | SNV | Missense_Mutation | novel | c.654G>T | p.Glu218Asp | p.E218D | Q309B1 | protein_coding | tolerated(0.31) | benign(0.058) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| TRIM16L | SNV | Missense_Mutation | novel | c.223A>G | p.Thr75Ala | p.T75A | Q309B1 | protein_coding | tolerated(0.9) | benign(0.02) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TRIM16L | SNV | Missense_Mutation | rs757995912 | c.283N>T | p.Arg95Cys | p.R95C | Q309B1 | protein_coding | deleterious(0.02) | benign(0.005) | TCGA-BG-A2L7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |